Management of the stroke patient with patent foramen ovale: New insights and persistent questions in the wake of recent randomized trials

Jessica M. Peña, Jorge Kizer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Stroke without a known cause, or cryptogenic stroke, accounts for up to 30 % of all ischemic strokes. Paradoxical embolism through a patent foramen ovale (PFO) has been implicated as a potential cause of cryptogenic cerebral ischemia, particularly in young patients. Epidemiological studies have noted an association between PFO and cryptogenic stroke and observational studies have suggested the potential superiority of percutaneous PFO closure over medical therapy. However, until recently, there were no randomized data to test the hypothesis that PFO closure reduces the risk of recurrent cerebral ischemia. The publication of three such trials, all failing to demonstrate a therapeutic advantage for closure over medical therapy in intention-to-treat analyses, provides valuable new data in the field. We review epidemiological evidence linking PFO and stroke and recent observational and randomized trial data evaluating different treatment strategies.

Original languageEnglish (US)
Article number338
JournalCurrent Atherosclerosis Reports
Volume15
Issue number7
DOIs
StatePublished - 2013

Fingerprint

Patent Foramen Ovale
Stroke
Brain Ischemia
Paradoxical Embolism
Intention to Treat Analysis
Therapeutics
Observational Studies
Publications
Epidemiologic Studies

Keywords

  • Cryptogenic stroke
  • Patent foramen ovale
  • Transient ischemic attack

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Management of the stroke patient with patent foramen ovale : New insights and persistent questions in the wake of recent randomized trials. / Peña, Jessica M.; Kizer, Jorge.

In: Current Atherosclerosis Reports, Vol. 15, No. 7, 338, 2013.

Research output: Contribution to journalArticle

@article{782c52db4b1844c7a0de4a16d58b86c9,
title = "Management of the stroke patient with patent foramen ovale: New insights and persistent questions in the wake of recent randomized trials",
abstract = "Stroke without a known cause, or cryptogenic stroke, accounts for up to 30 {\%} of all ischemic strokes. Paradoxical embolism through a patent foramen ovale (PFO) has been implicated as a potential cause of cryptogenic cerebral ischemia, particularly in young patients. Epidemiological studies have noted an association between PFO and cryptogenic stroke and observational studies have suggested the potential superiority of percutaneous PFO closure over medical therapy. However, until recently, there were no randomized data to test the hypothesis that PFO closure reduces the risk of recurrent cerebral ischemia. The publication of three such trials, all failing to demonstrate a therapeutic advantage for closure over medical therapy in intention-to-treat analyses, provides valuable new data in the field. We review epidemiological evidence linking PFO and stroke and recent observational and randomized trial data evaluating different treatment strategies.",
keywords = "Cryptogenic stroke, Patent foramen ovale, Transient ischemic attack",
author = "Pe{\~n}a, {Jessica M.} and Jorge Kizer",
year = "2013",
doi = "10.1007/s11883-013-0338-4",
language = "English (US)",
volume = "15",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "7",

}

TY - JOUR

T1 - Management of the stroke patient with patent foramen ovale

T2 - New insights and persistent questions in the wake of recent randomized trials

AU - Peña, Jessica M.

AU - Kizer, Jorge

PY - 2013

Y1 - 2013

N2 - Stroke without a known cause, or cryptogenic stroke, accounts for up to 30 % of all ischemic strokes. Paradoxical embolism through a patent foramen ovale (PFO) has been implicated as a potential cause of cryptogenic cerebral ischemia, particularly in young patients. Epidemiological studies have noted an association between PFO and cryptogenic stroke and observational studies have suggested the potential superiority of percutaneous PFO closure over medical therapy. However, until recently, there were no randomized data to test the hypothesis that PFO closure reduces the risk of recurrent cerebral ischemia. The publication of three such trials, all failing to demonstrate a therapeutic advantage for closure over medical therapy in intention-to-treat analyses, provides valuable new data in the field. We review epidemiological evidence linking PFO and stroke and recent observational and randomized trial data evaluating different treatment strategies.

AB - Stroke without a known cause, or cryptogenic stroke, accounts for up to 30 % of all ischemic strokes. Paradoxical embolism through a patent foramen ovale (PFO) has been implicated as a potential cause of cryptogenic cerebral ischemia, particularly in young patients. Epidemiological studies have noted an association between PFO and cryptogenic stroke and observational studies have suggested the potential superiority of percutaneous PFO closure over medical therapy. However, until recently, there were no randomized data to test the hypothesis that PFO closure reduces the risk of recurrent cerebral ischemia. The publication of three such trials, all failing to demonstrate a therapeutic advantage for closure over medical therapy in intention-to-treat analyses, provides valuable new data in the field. We review epidemiological evidence linking PFO and stroke and recent observational and randomized trial data evaluating different treatment strategies.

KW - Cryptogenic stroke

KW - Patent foramen ovale

KW - Transient ischemic attack

UR - http://www.scopus.com/inward/record.url?scp=84878136895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878136895&partnerID=8YFLogxK

U2 - 10.1007/s11883-013-0338-4

DO - 10.1007/s11883-013-0338-4

M3 - Article

C2 - 23715857

AN - SCOPUS:84878136895

VL - 15

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 7

M1 - 338

ER -